论文部分内容阅读
[目的]分析雌激素受体α、β(ERα、ERβ)和表皮生长因子受体(EGFR)在非小细胞肺癌(NSCLC)组织中的表达及其临床意义。[方法]采用MaxVision免疫组织化学技术检测59例NSCLC石蜡包埋组织中ERα、ERβ和EGFR的表达。[结果](1)ERα在肺癌组织及癌旁组织中均未见表达。ERβ在NSCLC中的阳性表达率为45.8%(27/59),EGFR在NSCLC中的阳性表达率为64.4%(38/59),而在癌旁组织中未见ERβ和EGFR的表达。(2)ERβ阳性表达与NSCLC组织学类型有关,在腺癌组织中的表达明显高于鳞癌,与性别、年龄、肿瘤大小、分化程度、TNM分期、淋巴结转移及吸烟状况无关;EGFR阳性表达与肿瘤组织的TNM分期及淋巴结转移相关,与性别、年龄、肿瘤大小、组织学类型、分化程度及吸烟状况无关。(3)腺癌中EGFR阳性表达并ERβ阳性表达与鳞癌相比有显著性差异。[结论]ERβ和EGFR可能在肺癌,尤其是腺癌的发生发展中发挥协同作用,由此可以通过同时靶向两个信号通路来治疗NSCLC。
[Objective] To analyze the expression of estrogen receptor α, β (ERα, ERβ) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) and its clinical significance. [Method] MaxVision immunohistochemistry was used to detect the expression of ERα, ERβ and EGFR in 59 NSCLC paraffin-embedded tissues. [Results] (1) ERα was not expressed in lung cancer tissues and adjacent tissues. The positive expression rate of ERβ in NSCLC was 45.8% (27/59). The positive expression rate of EGFR in NSCLC was 64.4% (38/59), while no expression of ERβ and EGFR was found in adjacent tissues. (2) The positive expression of ERβ correlated with the histological type of NSCLC, and was significantly higher in adenocarcinoma than that in squamous cell carcinoma. The positive expression of ERβ was not related to sex, age, tumor size, differentiation, TNM stage, lymph node metastasis and smoking status. It was correlated with TNM staging and lymph node metastasis of tumor, regardless of gender, age, tumor size, histological type, degree of differentiation and smoking status. (3) The positive expression of EGFR and the positive expression of ERβ in adenocarcinoma were significantly different from those of squamous cell carcinoma. [Conclusion] ERβ and EGFR may play synergistic roles in the development of lung cancer, especially adenocarcinoma. Therefore, NSCLC can be treated by targeting both signaling pathways simultaneously.